One of the largest pharmaceutical companies in the world, GW Pharmaceuticals, has six cannabis-derived medicine patents currently under review with the USPTO and several others pending the results of their clinical studies.
Upon being granted their patents, and it's going to happen, cannabis will be rescheduled in this country because it will officially be medicine recognized and approved by the FDA.
GW Pharmaceuticals plc (NASDAQ)
A biopharmaceutical company involved in research in cannabinoid compounds for use as prescription medicines to treat human diseases.
Clinical Studies: Dravet Syndrome, Epilepsy, Lennox Gastaut
Syndrome
Drug: Epidiolex
Cara Therapeutics, Inc. — (NASDAQ)
Cara Therapeutics is developing cannabinoid therapeutic methods to treat various disease.
Clinical Studies: Pruritis, Severe Pain
Biotica Pharmaceuticals, Inc.
Biotica is developing natural cannabinoid combinations against neural disorders.
Clinical Studies: Autism, Alzheimer's disease, Cognitive support
Zynerba Pharmaceuticals — (NASDAQ)
Zynerba is developing synthetic cannabinoid.
Clinical Studies: Osteoarthritis, Adult epilepsy, Fragile X syndrome
Axim Biotechnologies, Inc. — AXIM
Axim is another biotech company doing research and development of cannabis-derived compounds for use in pharmaceutical, nutraceutical and cosmetic applications.
Corbus Pharmaceuticals Holdings, Inc. — CRBP
This company is developing a synthetic endocannabinoid-mimetic drug for treating chronic inflammation.
Insys Therapuetics, Inc. (NASDAQ)
This company is developing a specialty synthetics/natural CBD for various diseases.
Clinical Studies: Infantile spasm, Prader-Willisyndrome |
